Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($0.26), $0.03 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $16.87 million versus the consensus estimate of $15.68 million.

2024 Financial Guidance

Operating Expenses (excluding share-based compensation): The Company continues to expect full year 2024 R&D expenses of $30 million to $36 million and SG&A expenses of $45 million to $55 million, in each case excluding share-based compensation.
Share-Based Compensation: The Company continues to expect full year share-based compensation expenses of $18 million to $22 million.
Non-GAAP Net Profit / Loss: The Company expects levels of both non-GAAP losses and cash burn in the second half to be similar to first half actuals 2024.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.